Last updated: 3 July 2024 at 4:15pm EST

Huw Nash Net Worth




The estimated Net Worth of Huw M. Nash is at least $4.08 Milhão dollars as of 20 May 2024. Huw Nash owns over 50,000 units of Stoke Therapeutics stock worth over $737,000 and over the last 5 years he sold STOK stock worth over $2,474,889. In addition, he makes $869,855 as Chief Operating Officer e Chief Business Officer at Stoke Therapeutics.

Huw Nash STOK stock SEC Form 4 insiders trading

Huw has made over 27 trades of the Stoke Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of STOK stock worth $32,775 on 2 July 2024.

The largest trade he's ever made was selling 61,329 units of Stoke Therapeutics stock on 1 April 2024 worth over $811,383. On average, Huw trades about 11,988 units every 47 days since 2020. As of 20 May 2024 he still owns at least 50,000 units of Stoke Therapeutics stock.

You can see the complete history of Huw Nash stock trades at the bottom of the page.





Huw Nash biography

Dr. Huw M. Nash is Chief Operating Officer, Chief Business Officer of the Company. Dr. Nash also served as an Entrepreneur-in-Residence at Apple Tree Partners, a venture capital firm. While at Apple Tree Partners, Dr. Nash was part of the founding group of entrepreneurs who worked on the original platform technology for Aileron Therapeutics, Inc., a biopharmaceutical company. Dr. Nash also served as Vice President of Corporate Development at Aileron Therapeutics, Inc. from 2005 to 2013. Prior to joining Aileron Therapeutics, Inc., Dr. Nash was a founding scientist of NeoGenesis Pharmaceuticals, Inc., a drug discovery company, where he served as Vice President of External Collaborations from 1997 to 2005 until its acquisition by Schering-Plough Corp. Dr. Nash holds a B.A. in Biochemical Sciences from Harvard College and a Ph.D. in Organic Chemistry from Harvard University.

What is the salary of Huw Nash?

As the Chief Operating Officer e Chief Business Officer of Stoke Therapeutics, the total compensation of Huw Nash at Stoke Therapeutics is $869,855. There are 3 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.



How old is Huw Nash?

Huw Nash is 53, he's been the Chief Operating Officer e Chief Business Officer of Stoke Therapeutics since 2017. There are 16 older and 5 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.

What's Huw Nash's mailing address?

Huw's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.

Insiders trading at Stoke Therapeutics

Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic..., eTrust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.



What does Stoke Therapeutics do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.



What does Stoke Therapeutics's logo look like?

Stoke Therapeutics, Inc. logo

Complete history of Huw Nash stock trades at Stoke Therapeutics

Data
#
Companhia
Acionista maioritário
Trans.
Transação
Ações Preço por ação Preço total Ações após Fonte
2 Jul 2024 Huw M. Nash
Chief Business Officer
Venda 2,500 $13.11 $32,775
2 Jul 2024
0
20 May 2024 Huw M. Nash
Chief Business Officer
Exercício de opção 50,000 $0.40 $20,000
20 May 2024
50,000
1 Apr 2024 Huw M. Nash
Chief Business Officer
Venda 61,329 $13.23 $811,383
1 Apr 2024
0
15 Mar 2024 Huw M. Nash
Chief Business Officer
Exercício de opção 13,100 $6.39 $83,709
15 Mar 2024
15,445
3 Jan 2022 Huw M. Nash
Chief Business Officer
Exercício de opção 3,800 $2.19 $8,322
3 Jan 2022
3,800
1 Dec 2021 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Dec 2021
5,700
1 Nov 2021 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Nov 2021
1,900
1 Oct 2021 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Oct 2021
5,700
1 Sep 2021 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Sep 2021
5,700
2 Aug 2021 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
2 Aug 2021
5,700
1 Jul 2021 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Jul 2021
5,700
1 Jun 2021 Huw M. Nash
Chief Business Officer
Exercício de opção 575 $2.19 $1,259
1 Jun 2021
575
4 Jan 2021 Huw M. Nash
Chief Business Officer
Venda 5,732 $58.96 $337,959
4 Jan 2021
0
17 Dec 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 50,000 $0.60 $30,000
17 Dec 2020
8,015
1 Dec 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Dec 2020
5,700
10 Nov 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 50,000 $1.03 $51,500
10 Nov 2020
50,000
2 Nov 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
2 Nov 2020
5,700
1 Oct 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Oct 2020
5,700
8 Sep 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 47,919 $2.19 $104,943
8 Sep 2020
17,201
1 Sep 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
1 Sep 2020
5,700
28 Aug 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 2,081 $2.19 $4,557
28 Aug 2020
2,081
3 Aug 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 5,700 $2.19 $12,483
3 Aug 2020
5,700
16 Jul 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 1,900 $2.19 $4,161
16 Jul 2020
1,900
7 Jul 2020 Huw M. Nash
Chief Business Officer
Venda 913 $22.41 $20,460
7 Jul 2020
0
1 Jul 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 3,800 $2.19 $8,322
1 Jul 2020
3,800
1 Jun 2020 Huw M. Nash
Chief Business Officer
Exercício de opção 2,107 $2.19 $4,614
1 Jun 2020
2,107
2 Mar 2020 Huw M. Nash
Chief Business Officer
Venda 49,143 $25.89 $1,272,312
2 Mar 2020
0


Stoke Therapeutics executives and stock owners

Stoke Therapeutics executives and other stock owners filed with the SEC include: